Literature DB >> 277260

Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer.

M V Alvarez, G Cobreros, A Heras, M C Lopez Zumel.   

Abstract

Cis-dichlorodiammineplatinum (II) (cisDDP) has been extensively studied as an antitumour agent; its binding to DNA has been proved but the radiosensitizing action has scarcely been tested. We report here that on TC.SV -40 mammalian cells cisDPP acts as a dose-modifying factor for ionizing radiation. The radiosensitizing action can be induced by two different mechanisms: reaction with non protein-SH groups and inhibition of repair processes. The cisDDP-DNA complex was studied against increasing radiation doses by analytical centrifugation and by spectrophotometrical measurements. The native complex seems to be more radiation resistant than the denatured one.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277260      PMCID: PMC2149413     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  7 in total

1.  New platinum complexes with anti-tumour activity.

Authors:  T A Connors; M Jones; W C Ross; P D Braddock; A R Khokhar; M L Tobe
Journal:  Chem Biol Interact       Date:  1972-11       Impact factor: 5.192

2.  Effect of cis-dichlorodiamine platinum (II) on the post-irradiation lethality in mice after irradiation with X-rays.

Authors:  M Zák; J Drobník
Journal:  Strahlentherapie       Date:  1971-07

3.  Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo.

Authors:  J A Howle; G R Gale
Journal:  Biochem Pharmacol       Date:  1970-10       Impact factor: 5.858

4.  Platinum compounds: a new class of potent antitumour agents.

Authors:  B Rosenberg; L VanCamp; J E Trosko; V H Mansour
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

5.  Non-protein sulfhydryl content and cell-cycle dynamics of Ehrlich ascites tumor.

Authors:  J W Harris; H M Patt
Journal:  Exp Cell Res       Date:  1969-07       Impact factor: 3.905

6.  Interaction of cis-dichlorodiammineplatinum (II) with DNA.

Authors:  P Horácek; J Drobník
Journal:  Biochim Biophys Acta       Date:  1971-12-16

7.  Coordination complexes of platinum as antitumor agents.

Authors:  R J Speer; H Ridgway; L M Hall; D P Stewart; K E Howe; D Z Lieberman; A D Newman; J M Hill
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun
  7 in total
  5 in total

1.  Targeted infusions of supradose Cisplatin with systemic neutralization for carcinomas invading the temporal bone.

Authors:  K T Robbins; P K Pelliteri; D Vicario; C W Kerber; J H Robertson; C Hanchett; S B Howell
Journal:  Skull Base Surg       Date:  1996

Review 2.  [Cis-diamminedichloroplatinum(II). A new antineoplastic agent derived from the group of heavy metal complexes (author's transl)].

Authors:  R Osieka; C G Schmidt
Journal:  Klin Wochenschr       Date:  1979-12-03

Review 3.  Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury.

Authors:  Kranti A Mapuskar; Emily J Steinbach; Amira Zaher; Dennis P Riley; Robert A Beardsley; Jeffery L Keene; Jon T Holmlund; Carryn M Anderson; Diana Zepeda-Orozco; John M Buatti; Douglas R Spitz; Bryan G Allen
Journal:  Antioxidants (Basel)       Date:  2021-08-24

4.  Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

Authors:  M Matsutani; O Nakamura; M Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; K Ueki; Y Tanaka
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.

Authors:  K Kiura; H Ueoka; Y Segawa; M Tabata; H Kamei; N Takigawa; S Hiraki; Y Watanabe; A Bessho; K Eguchi; N Okimoto; S Harita; M Takemoto; Y Hiraki; M Harada; M Tanimoto
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.